珍宝岛：分公司获得富马酸卢帕他定化学原料药上市申请批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Lurasidone, a long-acting antihistamine for allergic rhinitis and urticaria in adults and adolescents aged 12 and above [1] Group 1: Product Details - Fumaric Acid Lurasidone is indicated for allergic rhinitis and urticaria in patients aged 12 and older [1] - The total sales amount for Fumaric Acid Lurasidone tablets in public hospitals and key retail terminals in China is projected to be approximately 327 million yuan in 2024 [1] - The raw material usage for this drug is estimated at 0.21 tons [1] Group 2: R&D Investment - The company has invested approximately 6.6526 million yuan in the research and development of this raw material drug project [1]